6533b824fe1ef96bd12800c9
RESEARCH PRODUCT
Erythrocyte Phospholipid and Polyunsaturated Fatty Acid Composition in Diabetic Retinopathy
Rodica IsaicoLionel BretillonOlivier BerdeauxPhilippe KoehrerStéphanie CabaretNiyazi AcarCatherine Creuzot-garcherAlain M. BronStéphane GrégoireSarah Saabsubject
MaleOrganes des senslcsh:MedicineType 2 diabetesBiochemistrySeverity of Illness Indexchemistry.chemical_compoundMELLITUS0302 clinical medicineMedicine and Health SciencesMedicineOXIDATIVE STRESSlcsh:ScienceRETINAPhospholipidschemistry.chemical_classification0303 health sciencesCOMPLICATIONSMultidisciplinaryINSULIN SENSITIVITYFatty AcidsDiabetic retinopathyMiddle AgedLipids3. Good healthDocosahexaenoic acid[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansFatty Acids UnsaturatedPhosphatidylcholinesRetinal DisordersArachidonic acidlipids (amino acids peptides and proteins)FemalePolyunsaturated fatty acidRetinopathyResearch ArticleEXPRESSIONAdultmedicine.medical_specialtySensory OrgansPlasmalogensPhospholipidMédecine humaine et pathologie030209 endocrinology & metabolism03 medical and health sciencesInternal medicineDiabetes mellitus[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyDiabetes MellitusHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansRetinopathy030304 developmental biologyAgedDiabetic Retinopathybusiness.industryPhosphatidylethanolamineslcsh:RErythrocyte MembraneBiology and Life SciencesDOCOSAHEXAENOIC ACIDmedicine.diseaseLipid MetabolismENDOTHELIAL-CELLSDOCOSAHEXAENOIC ACID;INSULIN SENSITIVITY;ENDOTHELIAL-CELLS;OXIDATIVE STRESS;RETINA;LIPIDS;DEFORMABILITY;COMPLICATIONS;EXPRESSION;MELLITUSOphthalmologyEndocrinologyDiabetes Mellitus Type 1chemistryDiabetes Mellitus Type 2Metabolic DisordersCase-Control Studieslcsh:QHuman health and pathologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDEFORMABILITYdescription
Background: Long chain polyunsaturated fatty acids (LCPUFAs) including docosahexaenoic acid and arachidonic acid are suspected to play a key role in the pathogenesis of diabetes. LCPUFAs are known to be preferentially concentrated in specific phospholipids termed as plasmalogens. This study was aimed to highlight potential changes in the metabolism of phospholipids, and particularly plasmalogens, and LCPUFAs at various stages of diabetic retinopathy in humans. Methodology and Principal Findings: We performed lipidomic analyses on red blood cell membranes from controls and mainly type 2 diabetes mellitus patients with or without retinopathy. The fatty acid composition of erythrocytes was determined by gas chromatography and the phospholipid structure was determined by liquid chromatography equipped with an electrospray ionisation source and coupled with a tandem mass spectrometer (LC-ESI-MS/MS). A significant decrease in levels of docosahexaenoic acid and arachidonic acid in erythrocytes of diabetic patients with or without retinopathy was observed. The origin of this decrease was a loss of phosphatidyl-ethanolamine phospholipids esterified with these LCPUFAs. In diabetic patients without retinopathy, this change was balanced by an increase in the levels of several phosphatidyl-choline species. No influence of diabetes nor of diabetic retinopathy was observed on the concentrations of plasmalogen-type phospholipids. Conclusions and Significance: Diabetes and diabetic retinopathy were associated with a reduction of erythrocyte LCPUFAs in phosphatidyl-ethanolamines. The increase of the amounts of phosphatidyl-choline species in erythrocytes of diabetic patients without diabetic retinopathy might be a compensatory mechanism for the loss of LC-PUFA-rich phosphatidyl-ethanolamines.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-09-01 | PLoS ONE |